Autopsy report · NCT03700294

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

“Change in clinical plan and drug supply”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year before it stopped.
• 18 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

ADC Therapeutics S.A.

Sponsor type

Industry

Conditions

Advanced Solid Tumors

Interventions

ADCT-601

Participants

18

Sites

4

Countries

United States

Trials that died the same way

• Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
  “Changes in drug development plans” (74% match in meaning)
• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (74% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (71% match in meaning)
• A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
  “Change in clinical strategy” (68% match in meaning)
• Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee
  “Amended clinical development plan.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.